Small interfering RNA-mediated downregulation of \( \beta \)-catenin inhibits invasion and migration of colon cancer cells \textit{in vitro}

Jianjun Han\textsuperscript{1*}, Binbin Gao\textsuperscript{2*}, Xing Jin\textsuperscript{2}, Zhongfa Xu\textsuperscript{1E}, Zengjun Li\textsuperscript{1I}, Yanlai Sun\textsuperscript{1D}, Bao Song\textsuperscript{3B}

\* Contributed equally

\textsuperscript{1} Department of General Surgery, Shandong Cancer Hospital and Institute, Ji'nan, P.R. China
\textsuperscript{2} Department of Vascular Surgery, Shandong Provincial Hospital, Shandong University, Ji'nan, P.R. China
\textsuperscript{3} Department of Basic Research Center, Shandong Cancer Hospital and Institute, Ji'nan, P.R. China

Source of support: This work was funded by the Natural Science Fund of Shandong Province, China (No. ZR2009CM138)

Summary

Background: Abnormal regulation of Wnt/\( \beta \)-catenin signaling and subsequently increased \( \beta \)-catenin expression have been found to be involved in the proliferation and growth of colon cancer cells. Whether the down-regulation of \( \beta \)-catenin in colon cancer may result in compromised invasion and migration \textit{in vitro} still remains to be determined.

Material/Methods: A human colon cancer cell line (LoVo cells) was transfected with small interfering RNA (siRNA) targeting \( \beta \)-catenin. RT-PCR, Western blot assay, flow cytometry, cell adhesion assay, scratch wound assay, and matrigel invasion assay were performed, and the correlation between cell invasion and migration and \( \beta \)-catenin expressions was analyzed.

Results: siRNA-mediated down-regulation of \( \beta \)-catenin elevated the E-cadherin expression but reduced the MMP-7 and CD44v6 expressions, which increased the adhesion between LoVo cells but decreased the adhesion of LoVo cells to fibronectin. Significant inhibition of cell invasion and migration was also observed following RNA interference with \( \beta \)-catenin siRNA.

Conclusions: siRNA-mediated downregulation of \( \beta \)-catenin could be valuable for defining gene expression and functional programs downstream of oncogenic \( \beta \)-catenin signals, which, in turn, may be helpful to isolate novel diagnostic markers, and for designing tumor-specific intervention at downstream targets of oncogenic \( \beta \)-catenin.

key words: \( \beta \)-catenin • RNA interference • invasion • migration • colon cancer

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=883205

Word count: 3005

Tables: –

Figures: 7

References: 39

Author’s address: Zhongfa Xu, Department of General Surgery, Shandong Tumor Hospital and Institute, 440# Jiyan Road, Ji’nan, 250117, P.R. China, e-mail: bossxuxu@126.com

© Med Sci Monit, 2012; 18(7): BR273-280
PMID: 22739727
www.MedSciMonit.com
Basic Research
BACKGROUND

β-catenin is a multi-functional protein that serves as a structural protein at the adherent junctions and acts as a transcriptional co-activator mediating the canonical Wnt signaling [1-4]. Its deregulation is important in the genesis of a number of human malignancies, particularly colorectal cancer [5]. Under physiological conditions, β-catenin mainly localizes in cell membranes and functions as a component of the E-cadherin/β-catenin complex to control cell-cell adhesion and influence cell migration. The cytosolic β-catenin is maintained at a low level through degradation by the “destruction complex” [6-8]. In this complex, Axin acts as a scaffold protein, upon which adenomatous polyposis coli (APC) tumor suppressor protein, glycogen synthase kinase 3β (GSK-3β) and casein kinase 1α (CK1α) bind to facilitate the sequential phosphorylation of β-catenin by kinase CK1α and GSK-3β. Accordingly, phosphorylated β-catenin is recognized by β-transducin-repeat-containing protein and constantly degraded by the ubiquitin-proteasome pathway. Upon ligation of Wnts to their receptors, composed of frizzled proteins and low-density lipoprotein receptor-related protein 5/6, the cytoplasmic protein disheveled (Dvl) is recruited, phosphorylated and activated. Activation of Dvl induces the dissociation of GSK-3β from Axin and leads to the inhibition of GSK-3β. Next, the phosphorylation and degradation of β-catenin is inhibited as a result of the inactivation of the “destruction complex”. Subsequently, stabilized β-catenin translocates into the nucleus. Nuclear β-catenin is the ultimate effector, binding to Tcf/Lef (T-cell factor /lymphoid enhancing factor) to activate transcription of downstream genes, including c-myc [9], cyclin D1 [10], MMP7 [11], and CD44 [12], which are involved in the control of cellular proliferation, differentiation, apoptosis, invasion and metastasis [13,14].

In the majority of colorectal cancers, abnormally high amounts and stabilization of β-catenin accompanied by mutations in APC or β-catenin gene have been detected, and it has been suggested that the transcriptional activation of β-catenin/TCF plays a critical role in colon carcinogenesis [15]. The APC protein, which acts as a tumor suppressor protein, can down-regulate the transcriptional activation mediated by Wnt/β-catenin, but the protein products of mutant APC genes present in colorectal tumors were defective in this activity. Furthermore, mutations of β-catenin are common phosphorylation motifs in its NH2-terminal domain.

Suppression of β-catenin gene expression with either antisense oligodeoxynucleotide or small interfering RNA (siRNA) has been attempted to further confirm its potential role in the neoplastic growth of colon cancer cells [15,16]. Systemic administration of β-catenin antisense oligodeoxynucleotide inhibited proliferation, anchorage-independent growth, and cellular invasiveness of APC-mutant human colon carcinoma cells, including SW480, Colo201, and DLD-1. After antisense-mediated suppression of β-catenin/Tcf transcriptional activity, there is a corresponding decrease in the expression of cyclin D1 [15]. Furthermore, siRNA directed against β-catenin significantly downregulated c-myc and cyclin D1 gene expression, leading to reduced growth of SW480 and HCT116 colon cancer cells in soft agar and in nude mice [16]. These studies indicate that β-catenin plays a critical role in the neoplastic growth of colon cancers and genes inactivating targeting of β-catenin may have potential as a therapeutic agent to treat colon cancer.

In the present study, the effect of β-catenin on the invasion and migration, 2 important malignant phenotypes of cancer cells, was investigated by DNA interference (RNAi) in colon cancer cells (LoVo cells) in vitro, which is important for better defining its role in maintaining the malignant phenotype.

MATERIAL AND METHODS

Cell line and culture

A highly metastatic human colon adenocarcinoma cell line (LoVo cells) with APC mutation was purchased from the Basic Research Center of Shandong Tumor Hospital & Institute. Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA) containing 10% fetal bovine serum (FBS; Sijiqing Biological Engineering Materials Co., Ltd, Hangzhou, China) in a humidified atmosphere with 5% CO₂ at 37°C.

RNA oligonucleotides and transfection

According to the sequence in the study of Verma et al. [16], small interfering RNA (siRNA) targeting β-catenin (CTNNB1, NM001904) was synthesized by Shanghai GenePharma Co., Ltd. The sense was 5′-AGCGUGAUUAUGUGAGACGdTdTT-3′, which extends between amino acids 79 and 85 of β-catenin. A scrambled siRNA without homology to any mammalian gene sequence served as a negative control. The sense was 5′-GUCAUAGCUCUACUGAAGGdUTdT-3′.

LoVo cells in logarithmic phase were harvested by trypsinization and seeded at 1×10⁶ cells/well into 6-well plates to yield 80–90% confluence. Transfections were performed by using lipofectamine 2000 (Invitrogen) and 100 nM β-catenin-siRNA according to the manufacturer’s instructions. Medium was refreshed 6 h after transfection, and assay done 48 h after transfection.

RNA isolation and reverse transcription-PCR (RT-PCR)

Two days after transfection, cells were collected and homogenized in Trizol reagent (Invitrogen), and total RNA was extracted according to the manufacturer’s instructions. RT-PCR was performed by the SuperScript one-step method according to the manufacturer’s instructions (Invitrogen). The primers used in PCR were as follows: β-catenin: forward: 5′-ATCATGCGTGAGGGCTTACTGG-3′, reverse: 5′-CATCCCTTCCTGTTTAGTTGC-3′; β-actin: forward: 5′-AGCATCTCTAGAACTCTGTGC-3′, reverse: 5′-ATTCGAGCCCTGGAACATA-3′.

Western blot assay

Two days after transfection, LoVo cells were lysed in RIPA Lysis Buffer (Beyotime Institute of Biotechnology, Nanjing, China) on ice. Centrifugation was performed and supernatant collected for the analysis of protein concentration by BCA method. The extracted proteins were separated by sodium dodecysulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (Millipore, Billerica, USA) which were incubated overnight at 4°C with corresponding primary antibody and then with horseradish peroxidase (HRP) conjugated
secondary antibody (Zhongshan Biological Technology, Beijing, China). Primary antibodies included mouse anti-
β-catenin (sc-2963, Santa Cruz; 1: 500), mouse anti-E-cad-
herin (sc-21791, Santa Cruz; 1: 500), mouse anti-MMP-7 Ab-1
(Clone ID2, NeoMarkers; 1: 100), and mouse anti-β-actin.

Flow cytometry

Two days after transfection, cells were collected, washed twice
with phosphate buffer saline (PBS) and re-suspended in
100 µl of PBS containing 1% bovine serum albumin (BSA). Then,
FITC-labeled mouse anti-human CD44v6 monoclo-
nal antibody (Jingmei Biotech Co., Ltd., Shanghai, China)
was added to the suspension, followed by incubation for 30
min in dark at room temperature. FITC-labeled mouse IgG1
(Jingmei Biotech Co., Ltd., Shanghai, China) served as an
isotype control. The CD44v6 expression was measured by
flow cytometry (BD, Oxnard, USA). Gates were set to exclude
dead cells and a total of 10,000 gated cells were analyzed.

Test of homogeneity adhesion (between tumor cells)

LoVo cells (1×10⁴/well) were seeded into a 96-well plate to
yield 100% confluency. Then, LoVo cells that were trans-
ferred with β-catenin siRNA or scrambled siRNA for 48 h
were seeded into the same plate (1×10⁴/well), followed by
incubation for 2 h at 37°C. Then, the culture medium was
removed and cells were gently washed 3 times in PBS to col-
lect non-adherent cells followed by counting cell number.
The adhesion rate was calculated as adhesion rate = [1 −
(non-adherent cells/total cells)]×100%. The experiment
was performed in sextuplicate wells.

Test of heterogeneity adhesion (between tumor cells and
extracellular matrix)

A 96-well plate was treated with fibronectin (4 µg/well, R&D
Systems) overnight at 37°C. Then, non-specific adhesion
was excluded by incubating a plate with 100 µl of DMEM
containing 2% BSA for 1 h at 37°C. Following removal of
the above DMEM, LoVo cells (1×10⁴) that were transfect-
ed with siRNA were seeded into this 96-well plate, followed
by incubation for 2 h at 37°C. The adhesion rate was cal-
culated as above.

Scratch wound assay

The scratch wound assay was done as described previously [17].
Briefly, 24 h post-transfection, the confluent monolayer LoVo
cells were wounded with a plastic pipette tip, the dislodged
cells were removed by rinsing in PBS, then the wound area
of monolayer LoVo cells were photographed under a phase-con-
trast microscope and cells were incubated in DMEM at 37°C
in a humidified incubator with 5% CO₂. The ability of these
cells to migrate into the wound area was assessed at 24 and 48
h later. Cells were gently washed with PBS and the wound area
was photographed. Assay was performed in triplicate wells.

Matrigel invasion assay

The invasion activity of LoVo cells was measured as de-
scribed previously [18] with modifications. A 24-well tran-
swell chamber (Costar Co., USA) containing polycarbonate
membrane with a pore size of 8 µm was used. The upper
chambers were coated with 100 µl of Matrigel (1 mg/ml
BD). The membranes were rehydrated with warm serum-
free medium containing 2% BSA for 1 h. siRNA transfected
LoVo cells (2×10⁴ cells) were seeded into the upper cham-
er, and the lower chambers were filled with 600 µl of se-
rum-free DMEM containing 10 µg/ml fibronectin as a che-
moattractant. Incubation was performed for 24 h at 37°C
in a humidified incubator with 5% CO₂. Then, cells on the
top surface of the membranes were gently wiped off with
cotton swabs, and those that remained on the membranes
were then fixed in methanol and stained with crystal vio-
et. The invasive cells that were attached to the bottom sur-
face of the membranes were photographed and counted
under a microscope at a magnification of 400×. Five fields
were randomly selected and invasive cells were counted
and averaged. The experiment was performed in triplicate.

Statistical analysis

Quantitative data were expressed as mean ± standard deviation (SD) and analyzed by 2-sample t-test. Two-tailed P values
of <0.05 were accepted as statistically significant. Statistical
analysis was performed with the SPSS version 13.0 statisti-
cal software package (SPSS Inc., Chicago, IL).

RESULTS

β-catenin siRNA reduced mRNA and protein expression
of β-catenin in LoVo cells

A human colon cell line, LoVo, with APC mutation, results in
increased β-catenin levels. The increased levels of β-catenin
lead to the enhanced expression of β-catenin/TCF-regulated
genes. In this study, RNAi was used in an attempt to decrease
β-catenin expression in the cell lines. To identify whether
siRNA targeting β-catenin effectively inhibited β-catenin
expression in LoVo cells, RT-PCR and Western blot assay
were performed at 48 h after transfection. Results showed
both the mRNA and protein expressions of β-catenin were
significantly down-regulated in β-catenin siRNA transfect-
ed LoVo cells (Figures 1, 2). Collectively, these results indi-
cated significant knockdown of β-catenin mRNA and pro-
tein expression by β-catenin siRNA.

siRNA-mediated down-regulation of β-catenin regulated
expressions of E-cadherin, MMP-7 and CD44v6

The E-cadherin-catenin complex plays a crucial role in ep-
thelial cell-cell adhesion and in the maintenance of tissue
architecture. Perturbation in the expression or function of
this complex may result in loss of intercellular adhesion, with
possible consequent cell transformation and tumor progres-
sion. Re-establishment of adherent junctions in cancer cells
by restoration of cadherin expression [19] exerts tumor-sup-
pressive effects, including decreased proliferation and mo-
tility. MMP-7 is another target gene of β-catenin/TCF, it is
overexpressed in 80% of human colorectal cancers and is
known to be an important factor for early tumor growth,
with a potential function also for later progression steps such
as invasion and metastasis. CD44 is a cell surface molecule
that has diverse functions in cell-cell and cell-matrix inter-
actions and may be a determinant of metastasis and inva-
sive behavior in carcinomas. CD44v6 has been postulated
to be involved in both carcinogenesis and tumor progression.
We next examined whether β-catenin inhibition resulted in alterations in expressions of E-cadherin, MMP-7, and CD44v6. Western blot assay was performed and results revealed E-cadherin expression was elevated but MMP-7 expression down-regulated in cells following β-catenin siRNA transfection (Figure 3). As shown in Figure 4, flow cytometry indicated LoVo cells transfected with β-catenin siRNA displayed significantly lower CD44v6 expression (7.73±3.08) when compared with scrambled siRNA treated cells (13.29±4.04) \((P<0.001)\).

**Effects of β-catenin siRNA on cell adhesion**

SiRNA-mediated down-regulation of β-catenin regulated expressions of E-cadherin and CD44v6, which are closely related to intercellular and cell-matrix adhesion. To determine whether the β-catenin induced disruption of cell adhesion, cell adhesion assays were performed, and the results showed that the homogeneity and heterogeneity adhesion rates were 17.5±5.2\% and 67.7±6.9\%, respectively, in β-catenin siRNA-treated cells and 29.2±5.8\% and 32.3±5.1\%, respectively, in scrambled siRNA-treated cells, showing significant differences between the 2 groups. These findings suggest that siRNA-mediated down-regulation of β-catenin markedly reduced the homogeneity adhesion and increased the heterogeneity adhesion \((P<0.01)\) (Figure 5).

**Inhibition of cell migration by β-catenin siRNA**

To address whether β-catenin overexpression plays a role in regulating the invasion and migration of LoVo cells, we investigated the influence of β-catenin down-regulation on the LoVo cell migration by scratch wound assay. Results showed scrambled siRNA-treated LoVo cells markedly increased in the wound 24 h later, and the wound was almost entirely occupied 48 h later. By contrast, in the β-catenin siRNA treated cells, only a few cells were found in the wound area 24 h later, and the wound area was also clear even 48 h later. These findings demonstrate that β-catenin down-regulation significantly inhibited the migration ability of LoVo cells (Figure 6).

**Down-regulation of β-Catenin inhibited invasion of LoVo cells**

Previous work has demonstrated that the intranuclear localization of β-catenin increases cellular proliferation [20]. We further evaluated the invasion ability of β-catenin siRNA or scrambled siRNA-treated LoVo cells by matrigel invasion assay. Our results showed that after 24 h incubation, the number of β-catenin siRNA-treated cells across the matrigel-coated membrane was 68.8±8.7/5 fields, which was significantly lower than that of scrambled siRNA-treated LoVo cells (111.0±9.6/5 fields) \((P<0.001)\) (Figure 7).

**Discussion**

A characteristic feature of malignancies, including colon cancer, is the ability of cancer cells to invade surrounding tissues and migrate into distal tissues, which is a main cause of treatment failure and death in cancer patients. Thus, inhibition of invasion and metastasis of cancer cells has been a feasible strategy for the treatment of malignancies [21].
Abnormal regulation of Wnt/β-catenin signaling and subsequent increase of β-catenin expression has been found to promote cell proliferation and be related to carcinogenesis in colon cancer [22]. Whether β-catenin down-regulation in LoVo cells can compromise the invasion and migration potentials in vitro remains to be determined.

In the present study, our results showed that siRNA targeting β-catenin resulted in efficient and specific down-regulation of endogenous β-catenin at mRNA and protein levels in LoVo cells in vitro, and the siRNA-mediated β-catenin down-regulation dramatically inhibited the invasion and migration of LoVo cells, which may be related to the up-regulation of E-cadherin and reduction of CD44v6 and MMP-7 in LoVo cells.

The invasion and migration of cancer cells are complicated, multi-step processes involving the alteration of cell adhesion to extracellular matrix, as well as disruption of cell-cell junctions [23]. Liotta [24] proposed a 3-step hypothesis of tumor cell invasion of extracellular matrix: the first step is tumor cell attachment via cell surface receptors, which specifically bind to the components of matrix such as laminin and fibronectin; the second step is degradation of local matrix by tumor cell-associated proteases; and the third step is tumor cell locomotion into the region of matrix modified by proteolysis. Continued invasion of the matrix may take place by cyclic repetition of these steps.

In the present study, we assessed the invasion ability of LoVo cells in vitro by matrigel invasion assay, which is widely accepted as a biologically active basement membrane model to mimic the invasion process of tumor cells in vivo [25]. Our results showed siRNA-mediated down-regulation of β-catenin significantly inhibited the invasion of LoVo cells through the matrigel-coated transwell.

The decreased homogeneity adhesion and increased heterogeneity adhesion may contribute to the compromised migration of tumor cells from the primary site, and both homogeneity and heterogeneity adhesions are the basis for the invasion and metastasis of tumor cells [21]. Our results revealed siRNA-mediated down-regulation of β-catenin decreased the adhesion between LoVo cells and increased that of LoVo cells to fibronectin.

The invasion of tumor cells requires both migration and degradation of extracellular matrix [26]. Cell motility is a pivotal factor in metastasis and is necessary for migration through the matrix and entry into circulation, leading to
distant metastasis [27]. In our study, results showed that β-catenin siRNA significantly inhibited the degradation of extracellular matrix and the chemotaxis of LoVo cells across the matrigel-coated membrane toward fibronectin, a chemottractant. Scratch wound assay showed a slower wound-closure following transfection with β-catenin siRNA, indicating decreased motility of cancer cells.

A large number of genes relevant with tumor formation and progression have been found to be transcriptionally activated by the β-catenin/TCF complex [28], in which MMP-7 and CD44 are thought to play important roles in the invasion and metastasis of cancers [29,30]. In addition, E-cadherin/catenin complex controls cell-cell adhesion and influences cell migration [31,32]. To further elucidate the mechanism underlying the inhibition of adhesion, invasion and migration of LoVo cells followed β-catenin silencing, we detected the E-cadherin, CD44v6 and MMP-7 expression in LoVo cells after transfection. E-cadherin is a calcium-dependent adhesion molecule that mediates intercellular homogeneity adhesion, which widely exists in various types of epithelial cells. Our results showed the E-cadherin expression was significantly increased at 48 h after transfection when compared with scrambled siRNA-treated cells, suggesting
that siRNA-mediated down-regulation of β-catenin promotes the homogeneity adhesion of LoVo cells. CD44v6, a splice variant of adhesion molecule CD44, is involved in cell-matrix interactions and takes part in cell motility, and tumor growth, invasion and metastasis [33,34]. In this study, the CD44v6 expression in LoVo cells was markedly reduced at 48 h after β-catenin siRNA transfection. Proteases involved in degradation of extracellular matrix are indispensable for tumor cell invasion, which facilitates the migration of cancer cells through the basal membrane [35]. Among these proteases, matrix metalloproteinases (MMPs) appear to be particularly important [36], and the overproduction of MMPs has been associated with tumor growth and metastasis [37,38]. Moreover, MMP-7 has been found to be overexpressed in colon cancer [39]. Our results also revealed β-catenin down-regulation in LoVo cells significantly inhibited MMP-7 expression.

Conclusions

In conclusion, β-catenin over-expression may contribute to the invasion and migration of colon cancer cells through regulating E-cadherin, CD44v6 and MMP-7. siRNA-mediated β-catenin down-regulation dramatically inhibited the invasion and migration of LoVo cells, which may be attributed to the up-regulation of E-cadherin expression and down-regulation of CD44v6 and MMP-7 expressions in LoVo cells. We believe experiments such as that presented here are valuable for defining gene expression and functional programs downstream of oncogenic β-catenin signals. This, in turn, may be helpful to isolate novel diagnostic markers, and for designing tumor-specific intervention at downstream targets of oncogenic β-catenin.

Competing interests

All authors declare that they have no conflict of interest to disclose.

Abbreviations

APC – adenomatous polyposis coli; BSA – bovine serum albumin; DMEM – Dulbecco’s modified Eagle’s medium; MMP – matrix metalloproteinase; RNAi – RNA interference; siRNA – small interfering RNA; TCF – T-cell factor.

References:

1. Gayle-Rink J, Del Valle L, Sweet T et al: Developmental expression of Wnt signaling factors in mouse brain. Cancer Biol Ther, 2002; 1: 640–45
2. Streaker ED, Beckett D: The biotin regulatory system: kinetic control of a transcriptional switch. Biochemistry, 2006; 45: 6417–25
3. Xing Y, Takaneru K, Liu J et al: Crystal structure of a full-length β-catenin. Structure, 2008; 16: 478–87
4. Dchelus J, Cross MJ, Matsumoto T et al: Endostatin action and intracellular signalling: β-catenin as a potential target?. Cancer Lett, 2003; 196: 1–12
5. López-Knowles E, Zardawi SJ, McNeil CM et al: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev, 2010; 19: 301–9
6. Nelson WJ, Nuße R: Convergence of Wnt, β-catenin, and cadherin pathways. Science, 2004; 303: 1483–87
7. Janssou EA, Are A, Greicis G et al: The Wnt/β-catenin signaling pathway targets PPAR activity in colon cancer cells. Proc Natl Acad Sci USA, 2005; 102: 1460–65
8. Cheng XX, Wang ZC, Chen XY et al: Correlation of Wnt-2 expression and β-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett, 2005; 223: 339–47
9. He TC, Sparks AB, Rago C et al: Identification of c-MYC as a target of the APC pathway. Science, 1998; 281: 1509–12
10. Shotton M, Zhirnike J, Simcha I et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA, 1999; 96: 5522–27
11. Brablett B, Jung A, Dag S et al: beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol, 1999; 155: 1033–38
12. Wierenga VJ, Smits R, Koirnke V et al: Expression of CD44 in Apo and Tcf mutant mice implies regulation by the Wnt pathway. Am J Pathol, 1999; 154: 515–25
13. Ge X, Wang X: Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol, 2010; 3: 33
14. Wong NA, Pigatelli M: β-catenin – a linchpin in colorectal carcinogenesis? Am J Pathol, 2002; 160: 389–401
15. Rob H, Green DW, Roswell CB et al: Suppression of β-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res, 2001; 61: 6563–68
16. Verma UN, Surabhi RM, Schmalteig A et al: Small interfering RNAs direct against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clinical Cancer Res, 2005; 9: 1291–300
17. Faux MC, Ross JL, Meeker C et al: Restoration of full-length adenoma- tosis polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J Cell Sci, 2004; 117: 427–39
18. Albini A, Beamont Y, Kleinman HK et al: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res, 1987; 47: 3239–45
19. Vlemingrck V, Vakaet L, Mareel M et al: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 1991; 66: 107–19
20. Romanı T, Zullo A, Borrini F et al: Relationship between beta-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia. World J Gastroenterol, 2005; 11: 4400–5
21. Wang Y, Yang H, Liu H et al: Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer, 2009; 9: 174
22. Choi BR, Gwak J, Kwon HM et al: Oligodeoxyribonucleotides that cleave β-catenin messenger RNA inhibit growth of colon cancer cells via reduction of β-catenin response transcription. Mol Cancer Ther, 2010; 9: 1894–902
23. Dasgupta P, Rzwin W, Pillai S et al: Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer, 2009; 124: 36–45
24. Liotta LA: Tumor invasion and metastasis – role of the extracellular matrix. Rhoads Memorial Award lecture. Cancer Res, 1986; 46: 1–7
25. Yuan K, Singh R, Rezonw G, Siegal G: Expression and mechanism of the Twist gene on invasion and metastasis of gastric carcinoma cells. World J Gastroenterol, 2006; 11: 4400–5
26. Su F, Li H, Yan C et al: Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells. J Cancer Res Clin Oncol, 2009; 135: 1655–63
27. Larkins TL, Nowell M, Singh S, Sanford GL: Inhibition of cyclooxygen-ase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer, 2006; 6: 181
28. Luo GQ, Li JJ, Wen JF et al: Correlation of Wnt-2 expression and β-catenin response transcription of breast cancer cells. Am J Pathol, 2002; 160: 389–401
29. Shiomi T, Okada Y: MT1-MMP and MMP-7 in invasion and metastasis of gastric cancer cells. Int J Cancer, 2009; 124: 36–45
30. Xu Y, Yu Q: E-cadherin negatively regulates CD44-hyaluronan interactions and participates in cellular adhesion. J Biol Chem, 2003; 278: 1894–902
31. Vleminckx K, Vakaet L, Mareel M et al: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 1991; 66: 107–19
32. Romiti R, Zullo A, Borrini F et al: Relationship between beta-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia. World J Gastroenterol, 2005; 11: 4400–5
33. Wx H, Yang H, Liu H et al: Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer, 2009; 9: 174
34. Choi BR, Gwak J, Kwon HM et al: Oligodeoxyribonucleotides that cleave β-catenin messenger RNA inhibit growth of colon cancer cells via reduction of β-catenin response transcription. Mol Cancer Ther, 2010; 9: 1894–902
34. Zhang JC, Wang ZR, Cheng YJ et al: Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes’ stage C or D. World J Gastroenterol, 2003; 9: 1482–86

35. Bellyei S, Schally AV, Zarandi M et al: GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett, 2010; 293: 31–40

36. Abécassis I, Olofsson B, Schmid M et al: RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res, 2003; 281: 363–76

37. Cousens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002; 295: 2387–92

38. Duffy MJ, Maguire TM, Hill A et al: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res, 2000; 2: 252–57

39. Kioi M, Yamamoto K, Higashi S et al: Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene, 2003; 22: 8662–70